Maintain CL at ≤3% benchmark weight with tightened $86.50 stop; reject trim as institutional flows defeat preemptive reduction at 200 SMA test
Maintain CL at or slightly below benchmark consumer staples weight with the $88.04 stop replaced by a hard exit at $86.50, below the September swing low and ~1.5 ATR below the 200 SMA. Do not trim preemptively—binding historical lessons from 9/16 and prior setups demonstrate that institutional flows absorb most downside at the 200 SMA test and defeat preemptive reductions without capturing meaningful alpha. The franchise carry ($3.46B TTM FCF covering $3.11B capital return, 60+ year dividend streak, 0.32 beta) provides structural floor that the bear cannot easily dismantle. The bearish stack (yield gap ~256bps, forward P/E ~21x, MACD most negative reading, RSI failing to reclaim 50) justifies the stop architecture and re-engagement framework but not a preemptive trim or exit at current levels. The $86.50 stop captures the empirical alpha ceiling on CL bearish expressions (roughly -2%) while preserving upside participation if the structural bid holds.
| Position | Action |
|---|---|
| Position size at or slightly below benchmark consumer staples weight | ≤3% of portfolio |
| No trim at current 200 SMA test levels | Reject preemptive reduction per 9/16 binding lesson |
| Confirmed close below $86.50 with volume >5M | Downgrade to Sell, reassess at $84.50 spring-low retest |
| Pullback to $82-84 zone with RSI <30 and bullish divergence | Scale into full benchmark weight |
The pullback is a textbook accumulation setup at a rising 200-day moving average support level, with momentum repairing, volatility compressing, and a Goldman Sachs-led $1B+ divestiture catalyst about to unlock shareholder value.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 90.86 | bearish |
| close_200_sma | 87.32 | neutral |
| close_10_ema | 88.04 | bearish |
| rsi | 41.22 | neutral |
| macd | -1.12 | bearish |
| macds | -0.92 | bearish |
| atr | 1.69 | neutral |
| vwma | 88.66 | bearish |
| close | 87.73 | neutral |
Support: 87.32 · 85.89 · 86.8 | Resistance: 88.04 · 88.66 · 89.38
CL is testing its 200 SMA at $87.32 as critical support in a multi-timeframe bearish alignment, with price below both the 10 EMA (88.04) and 50 SMA (90.86). RSI has recovered from oversold (33.47 on Sep-11) to 41.22 but remains below 50, while MACD momentum is deteriorating with both lines negative. ATR has contracted to $1.69 from $2.55, suggesting a coiled-spring volatility setup. VWMA at $88.66 confirms bearish distribution with volume declining alongside price. Final stance: HOLD.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Reclaim $90.86 (50 SMA) with positive MACD histogram
Then: Upgrade to Overweight at full benchmark weight
$1B+ divestiture is the largest near-term catalyst with Goldman Sachs advising
↩ rebuts: “Bear thesis treats divestiture as a 'watch item' rather than active catalyst”
EV: $92-94 (reclaim 50 SMA + Bollinger midline) within 60-90 days; +3.6% upside to $90.86 · concedes: MACD histogram is deepening negative at −1.12 vs signal −0.92; Geopolitical risk from Iran/Hormuz affects palm oil and petrochemical packaging inputs; Mass-market personal care has been structurally low-margin and low-growth; Near-term North America softness requires execution on premium innovation, ad spend, and pricing levers; Current price is below 50 SMA at $90.86 and 10 EMA at $88.04
CL's setup is distribution disguised as accumulation, with the stock precariously positioned 47 basis points above the 200 SMA ($87.32), trading below the declining 20-day VWMA, with RSI sub-50 and MACD deepening negative—creating asymmetric downside risk rather than the coiled-spring breakout the bull case suggests.
· concedes: 200 SMA has held multiple times — I respect the level; S&P 500 low beta (0.32) provides some downside volatility protection; Scale is real, though without organic growth it's just overhead; FCF coverage is 1.87x — that number is real; FCF is currently covering the dividend today; Geopolitical risk is partially in the price; Strong dollar headwind is acknowledged by the bull; Hill's Pet Nutrition is a top-3 global position; Distribution scale in 200+ countries is genuine
→ vs conservative: Dividend King status and 1.87x FCF coverage are not a floor when yield at 2.44% is below risk-free rate of 4.5%; conservative anchors on absolute yield rather than risk-adjusted comparison; 24/7 Wall St. flagged payout ratio concerns making dividend itself under scrutiny
→ vs conservative: 200 SMA slope argument is backward looking; price clinging to 200 SMA by 41 cents is structural uptrend on life support, not intact; slope will flatten or break as price action confirms distribution
→ vs conservative: Waiting for MACD histogram to turn less negative and RSI above 50 is a re-entry framework for BUILDING a long position, not for managing an existing position; confusion of frameworks
→ vs conservative: 10% recession probability doesn't fix a 2% organic grower at 21x forward with PEG of 1.59; soft landing narrative cannot justify valuation premium when no growth or yield present
→ vs conservative: 74.55 at 15% tail 'rarely happens' but it already happened in 2022 and 2024; consumer staples round trip 20-25% on multiple compression plus fundamental disappointment
→ vs neutral: 200 SMA at 87.32 is being tested TODAY; waiting for decisive break below means chasing 5-10% move to 83 with no entry advantage; waiting for car to be fully underwater before grabbing seatbelt is paralysis, not risk management
→ vs neutral: 'Awaiting catalyst' in a stock with negative MACD, price below all moving averages, RSI at 41 is holding through pain; VWMA confirms distribution with sellers in control of tape
→ vs neutral: 'Balanced risk-reward' language is enemy of returns; in confirmed distribution with one-directional momentum, 'balanced' means slowly bleeding
→ vs neutral: $1 billion divestiture at 1.4% of market cap is not a re-rating catalyst; 'structural transformation via divestiture' plus 'tactical recovery' are two unknowns compounding; story stock masquerading as defensive
Market Cap
$69.94 B
Beta
0.323
Dividend Yield
2.44%
52-Week High
$99.33
52-Week Low
$74.55
50-Day Avg
$91.04
200-Day Avg
$88.00
Q2 2026 Revenue
$5,361 M
Q2 2026 Gross Profit
$3,296 M
Q2 2026 Operating Income
$1,016 M
Q2 2026 Net Income
$693 M
Q2 2026 Diluted EPS
$0.86
Q2 2026 Gross Margin
61.5%
FY2025 Revenue
$20.38 B
FY2025 Gross Profit
$12.25 B
FY2025 Operating Income
$4.23 B
FY2025 Net Income
$2.13 B
FY2025 Diluted EPS
$2.63
FY2025 Operating Margin
20.8%
FY2025 Free Cash Flow
$3.63 B
FY2025 Dividends Paid
$1.82 B
FY2025 Buybacks
$1.21 B
TTM Revenue
$21.05 B
TTM EBITDA
$4.98 B
TTM Operating Margin
20.97%
TTM Profit Margin
9.68%
TTM Free Cash Flow
$3.46 B
FCF Yield
~4.9%
ROE (TTM)
267%
ROA (TTM)
15.84%
Cash & Equivalents
$1.37 B
Inventory
$2.18 B
Receivables
$1.96 B
Total Current Assets
$6.31 B
Goodwill & Intangibles
$4.60 B
Net PPE
$4.64 B
Total Assets
$16.79 B
Long-Term Debt
$7.82 B
Total Debt
$7.86 B
Total Equity
$236 M
Net Debt
$6.49 B
Debt/EBITDA
~1.58x
Current Ratio
1.026
Book Value/Share
$0.30
Diluted Shares Outstanding
~797.2 M
TTM P/E
34.54x
Forward P/E
21.36x
EV/EBITDA (TTM)
~15.3x
PEG Ratio
1.59
Q4 2025 Impairment
$919 M
Q2 2026 Dividend Per Share
$0.58/qtr
FY2021 Revenue
$17.42 B
FY2022 Revenue
$17.97 B
FY2023 Revenue
$19.46 B
FY2024 Revenue
$20.10 B
FY2025 EPS
$2.63
FY2024 EPS
$3.51
FY2023 EPS
$2.77
FY2022 EPS
$2.13
FY2021 EPS
$2.13
Interest Expense FY2025
$267 M
Revenue CAGR 2021-2025
4.0%
Strengths
Concerns
Colgate-Palmolive is a high-quality consumer-defensive franchise with a ~30%+ global toothpaste market share, trading at a forward P/E of ~21x with improving 2026 operating momentum (Q2'26 revenue $5.36B, operating margin 19%) and strong FCF generation ($3.46B TTM, FCF yield ~4.9%). The company is a Dividend Aristocrat with 25+ years of consecutive dividend increases, maintains ~61.5% gross margins demonstrating pricing power, and is actively deleveraging with net debt declining from $7.54B to $6.49B year-over-year, though FY2025 EPS was artificially depressed to $2.63 by a $919M non-cash goodwill impairment.
Macro: Fed futures pricing 95% probability of zero rate cuts in 2026 (+2.7pp w/w); Polymarket inflation: P(<5%)=92%, P(>4.5%)=20% (+7pp w/w), P(>6%)=5%; Recession risk: US 10%, UK 10%, Japan 6% (1pp up w/w); Geopolitical: U.S.-Iran conflict $38B through Aug 1, $3B/month, Strait of Hormuz focus; Canada CPI 3% YoY August (above BoC 2% target, services sticky)